NZ602648A - Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers - Google Patents

Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Info

Publication number
NZ602648A
NZ602648A NZ602648A NZ60264811A NZ602648A NZ 602648 A NZ602648 A NZ 602648A NZ 602648 A NZ602648 A NZ 602648A NZ 60264811 A NZ60264811 A NZ 60264811A NZ 602648 A NZ602648 A NZ 602648A
Authority
NZ
New Zealand
Prior art keywords
mixture
water
acetone
carbon atoms
aliphatic ketone
Prior art date
Application number
NZ602648A
Other languages
English (en)
Inventor
Claudio Giordano
Erwin Waldvogel
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ602648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Priority to NZ700221A priority Critical patent/NZ700221A/en
Publication of NZ602648A publication Critical patent/NZ602648A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ602648A 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers NZ602648A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ700221A NZ700221A (en) 2010-04-27 2011-04-06 Ralfinamide methanesulfonate salts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161207 2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Publications (1)

Publication Number Publication Date
NZ602648A true NZ602648A (en) 2014-10-31

Family

ID=42634917

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ602648A NZ602648A (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
NZ700221A NZ700221A (en) 2010-04-27 2011-04-06 Ralfinamide methanesulfonate salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ700221A NZ700221A (en) 2010-04-27 2011-04-06 Ralfinamide methanesulfonate salts

Country Status (27)

Country Link
US (2) US9505708B2 (https=)
EP (1) EP2563355B1 (https=)
JP (3) JP5808392B2 (https=)
KR (1) KR101851118B1 (https=)
CN (2) CN102858330B (https=)
AR (1) AR085171A1 (https=)
AU (1) AU2011246707B2 (https=)
BR (1) BR112012027623B1 (https=)
CA (1) CA2794389C (https=)
CY (1) CY1117879T1 (https=)
DK (1) DK2563355T3 (https=)
EA (1) EA021389B1 (https=)
ES (1) ES2590128T3 (https=)
HR (1) HRP20161077T1 (https=)
HU (1) HUE030504T2 (https=)
IL (1) IL222532A (https=)
LT (1) LT2563355T (https=)
ME (1) ME02509B (https=)
MX (1) MX342697B (https=)
NZ (2) NZ602648A (https=)
PL (1) PL2563355T3 (https=)
PT (1) PT2563355T (https=)
RS (1) RS55084B1 (https=)
SI (1) SI2563355T1 (https=)
SM (1) SMT201600266B (https=)
TW (1) TWI492919B (https=)
WO (1) WO2011134763A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5808392B2 (ja) * 2010-04-27 2015-11-10 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310B (zh) * 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
AU2004266494B2 (en) 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
CA2936209C (en) * 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
BRPI0821026A2 (pt) 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
JP5808392B2 (ja) * 2010-04-27 2015-11-10 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法

Also Published As

Publication number Publication date
US9856207B2 (en) 2018-01-02
DK2563355T3 (en) 2016-09-12
CA2794389A1 (en) 2011-11-03
BR112012027623B1 (pt) 2021-07-06
CA2794389C (en) 2016-08-23
CN105037188A (zh) 2015-11-11
EA021389B1 (ru) 2015-06-30
CY1117879T1 (el) 2017-05-17
JP2017197553A (ja) 2017-11-02
HUE030504T2 (en) 2017-05-29
MX2012012093A (es) 2012-12-17
ES2590128T3 (es) 2016-11-18
TWI492919B (zh) 2015-07-21
US20170029365A1 (en) 2017-02-02
WO2011134763A1 (en) 2011-11-03
TW201139344A (en) 2011-11-16
CN105037188B (zh) 2017-06-23
CN102858330A (zh) 2013-01-02
JP6450420B2 (ja) 2019-01-09
JP2013528577A (ja) 2013-07-11
JP2015180664A (ja) 2015-10-15
EP2563355A1 (en) 2013-03-06
MX342697B (es) 2016-10-10
JP6345154B2 (ja) 2018-06-20
LT2563355T (lt) 2016-09-26
US20130039983A1 (en) 2013-02-14
SMT201600266B (it) 2016-08-31
KR101851118B1 (ko) 2018-04-23
EP2563355B1 (en) 2016-06-08
BR112012027623A2 (pt) 2016-08-09
AU2011246707B2 (en) 2014-11-20
SI2563355T1 (sl) 2016-10-28
HRP20161077T1 (hr) 2016-10-21
RS55084B1 (sr) 2016-12-30
HK1213872A1 (zh) 2016-07-15
PL2563355T3 (pl) 2016-12-30
EA201291116A1 (ru) 2013-04-30
CN102858330B (zh) 2015-07-22
PT2563355T (pt) 2016-09-02
ME02509B (me) 2017-02-20
JP5808392B2 (ja) 2015-11-10
IL222532A0 (en) 2012-12-31
AR085171A1 (es) 2013-09-18
IL222532A (en) 2017-09-28
KR20130094212A (ko) 2013-08-23
NZ700221A (en) 2016-04-29
US9505708B2 (en) 2016-11-29
HK1179881A1 (en) 2013-10-11

Similar Documents

Publication Publication Date Title
EP4023641A3 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
NZ602648A (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
NZ742200A (en) Treatment of osteoarthritis
NZ593647A (en) Synthesis of purine nucleosides
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JO3178B1 (ar) النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
CY1118107T1 (el) Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
BR112014014060A2 (pt) processo para a preparação de travoprosta
NZ589350A (en) Novel [F-18]-labelled L-glutamic acid- and L-glutamine derivatives (I), use thereof and method for their production
BR112013030973A8 (pt) processo para a preparação de amidas de prostaglandina
MX351176B (es) Método para producir y purificar sales del ácido acrilamido-2- metilpropan sulfónico.
TN2009000167A1 (en) Crystalline potassium salt of lipoxin a4 analogs
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
NZ628796A (en) Pure erlotinib
MD4350B1 (ro) Forma cristalină delta a sării de L-arginină a perindoprilului, procedeu de obţinere a ei şi compoziţii farmaceutice care o conţin
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
JP2013528577A5 (https=)
GEP20186827B (en) Process for synthesis of ulipristal acetate and its 4'-acetyl analogue
MX2016005231A (es) Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparacion y composiciones farmaceuticas del mismo.
HRP20230481T1 (hr) Čvrsti oblici inhibitora ttk

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 APR 2027 BY COMPUTER PACKAGES INC

Effective date: 20260317